Table 2.
Principal characteristics of the studies included in the meta-analysis.
| Included research and year | Stochastic method | Sample size (n) | Age (y) | Male (%) | Intervening measure | Duration | Outcome measures | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | T | C | T | C | ||||
| Hang et al. 2016 [18] | Random number table | 30 | 30 | 62.45 (7.12) | 62.62 (7.48) | 57% | 57% | C + TXLC 2–4 capsules each time, tid | Atorvastatin 20 mg/d | 8 W | ①⑧ |
| Liu and An 2016 [19] | NR | 80 | 80 | 54.5 (2.1) | 51.1 (1.4) | 61% | 65% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 20 mg/d | 3 M | ①④⑤⑥⑦⑨ |
| Qiao [20] | NR | 65 | 65 | 59.1 (6.5) | 58.8 (7.1) | 51% | 51% | C + TXLC 2 capsules each time, tid | Atorvastatin 20 mg/d | NR | ①⑨ |
| Song [21] | Random number table | 49 | 49 | 65.31 (10.42) | 64.97 (9.55) | 53% | 51% | C + TXLC 3 capsules each time, tid | Atorvastatin 20 mg/d | 3 M | ④⑤⑥⑨ |
| Nie [22] | NR | 39 | 39 | 55.31 (2.6) | 54.35 (2.17) | 56% | 54% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 1 tablet/d | 3 M | ①②③ |
| Li [23] | Random number table | 47 | 47 | 61.87 (5.31) | 62.34 (4.97) | 57% | 55% | C + TXLC 3 capsules each time, tid | CT + atorvastatin 20 mg/d | 8 W | ①②③④⑤⑧ |
| Yuan 2018 [24] | NR | 34 | 35 | 51.7 (3.2) | 51.7 (3.2) | 54% | 54% | C + TXLC 3 capsules each time, tid | Atorvastatin 10 mg/d | 4 W | ①④⑤⑥⑦⑧⑨ |
| Zhao et al. 2016 [25] | Random number table | 58 | 57 | 59.8 (7.6) | 59.0 (7.4) | 59% | 61% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 10 mg/d | 4 W | ①④⑤⑥⑧ |
| Qian 2014 [26] | NR | 46 | 46 | 64.91 (4.38) | 66.01 (4.45) | 52% | 59% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 20 mg/d | 3 M | ①④⑤⑥⑦⑧ |
| Qiao 2017 [27] | Random number table | 50 | 50 | 64.2 (4.9) | 65.1 (5.3) | 62% | 58% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 20 mg/d | 2 M | ①②③⑧ |
| Jiang et al. 2019 [28] | NR | 80 | 80 | 58.5 (6.4) | 59.1 (6.2) | 58% | 55% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 20 mg/d | 3 M | ①②⑧ |
| Wu 2017 [29] | Parity of hospital order | 70 | 70 | 58.5 (2.8) | 57.5 (3.5) | 53% | 46% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 1 tablet/d | 3 M | ①④⑤⑥⑦⑨ |
| Wang 2018 [30] | Random number table | 50 | 50 | 58.3 (2.6) | 58.3 (2.6) | 53% | 53% | C + TXLC 2 capsules each time, tid | CT + atorvastatin 10 mg/d | 1 M | ①②③ |
| Song and Ding 2012 [31] | NR | 49 | 49 | 52.64 (2.36) | 49.64 (3.36) | 55% | 49% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 20 mg/d | 3 M | ①④⑤⑥⑦⑨ |
| Zeng 2012 [32] | NR | 42 | 42 | 53.25 (3.51) | 49.03 (3.86) | 60% | 55% | C + TXLC 4 capsules each time, tid | CT + atorvastatin 20 mg/d | 3 M | ①④⑤⑥⑦ |
Note. M: month; W: week; D: day; T: treatment group; C: conventional group; CT: conventional treatment; TXLC: tongxinluo capsule; ① effectiveness of clinical treatment; ② frequency of angina pectoris; ③ duration of angina pectoris; ④ TC; ⑤ TG; ⑥ LDL-C; ⑦ HDL-C; ⑧ CRP; and ⑨ adverse reactions.